Floatz Rating
B62/100
Confidence
Indicative
Sponsor
Amsterdam UMC, location VUmc
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
53Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05861505CT.gov COLLISION RELAPSE Trial | — | Recruiting | — | — | — |
NCT05595889CT.gov Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05353582CT.gov Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases | — | Unknown | — | — | — |
NCT05262452CT.gov Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer | — | Unknown | — | — | — |
NCT04556071CT.gov Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer | — | Unknown | — | — | — |
NCT04447092CT.gov Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer | — | Unknown | — | — | — |
NCT03975049CT.gov Triplet Combination or Doublet Regimen Versus Chemoradiation as Neoadjuvant Therapy for Locally Advanced Rectal Cancer | — | Not Yet Recruiting | — | — | — |
NCT02484833CT.gov Erbitux MEtastatic Colorectal Cancer Strategy Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chemotherapy-Induced Toxicity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Irinotecan (this asset) | Amsterdam UMC, location VUmc | P3 | B · 62 |
| Dexasone | Instituto do Cancer do Estado de São Paulo | P4 | A |
| Palonosetron | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | A |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| HR20013 | Fujian Shengdi Pharmaceutical Co., Ltd. | P3 | BB |
| Docetaxel | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BB |
| Netupitant | Instituto Brasileiro de Controle do Cancer | P3 | BB |
| Carboplatin | Endeavor Health | P3 | BB |
| Ondansetron | Dr Atul Sharma | P3 | BB |
+42 more in the Chemotherapy-Induced Toxicity cohort
Other indications for Irinotecan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Rectal Cancer | — | P4 | BBB · 78 |
| Exocrine Pancreatic Carcinoma | — | P2/3 | BBB · 78 |
| Colon Adenocarcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DexasoneInstituto do Cancer do Estado de São PauloA
- PalonosetronSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityA
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBBB
- HR20013Fujian Shengdi Pharmaceutical Co., Ltd.BB
- DocetaxelThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBB
Citation
Floatz Terminal. Irinotecan in Chemotherapy-Induced Toxicity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/irinotecan-chemotherapy-induced-toxicity
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →